This document is a legal disclaimer page (page 14) from a Goldman Sachs presentation or report, bearing the Bates stamp HOUSE_OVERSIGHT_026922, indicating it was part of a US Congressional investigation. It details regulatory compliance, licensing exemptions, and restrictions for distributing financial materials in various jurisdictions including Australia, Brazil, Chile, Dubai, Israel, Singapore, and the UAE. It specifically notes that Goldman Sachs entities are not licensed to provide investment advice in Israel and outlines 'wholesale client' restrictions in Australia.
This document contains legal disclaimers and regulatory disclosures regarding financial services provided by Goldman Sachs entities across multiple jurisdictions, including Australia, Brazil, Chile, Dubai, and Israel. It specifies the regulatory bodies governing operations in each region, outlines restrictions on who may receive the materials (e.g., wholesale clients, sophisticated investors), and clarifying licensing exemptions.
This document is a legal disclaimer and regulatory disclosure page from a BofA Merrill Lynch financial research report dated June 30, 2016. It details the regulatory bodies and distribution entities governing the report's release across multiple global jurisdictions (UK, Japan, Hong Kong, Taiwan, etc.) and includes standard warnings regarding investment risks, conflicts of interest, and copyright. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production to the US House Oversight Committee.
This document is a 'Disclosures' page from a Bank of America Merrill Lynch research report titled 'Japan Economics Viewpoint,' dated November 18, 2016. It outlines legal disclaimers, conflict of interest policies, and regulatory information for various global jurisdictions where the bank operates. The document bears the House Oversight Committee stamp 'HOUSE_OVERSIGHT_014422', suggesting it was part of a larger production of documents, likely subpoenaed from financial institutions.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity